PriceTargets.com logo

Cronos Group - CRON Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $3.00
  • Forecasted Upside: 53.85%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.95 As of 12/20/2024 06:31 PM ET
▲ +0.08 (4.28%)

This chart shows the closing price for CRON by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cronos Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRON

Analyst Price Target is $3.00
▲ +53.85% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Cronos Group in the last 3 months. The average price target is $3.00, with a high forecast of $3.50 and a low forecast of $2.50. The average price target represents a 53.85% upside from the last price of $1.95.

This chart shows the closing price for CRON for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 investment analysts is to sell stock in Cronos Group. This rating has held steady since April 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/15/2024CIBCBoost TargetOutperformer ➝ Outperformer$3.00 ➝ $3.50
4/8/2024Bank of AmericaBoost TargetUnderperform ➝ Underperform$2.00 ➝ $2.50
12/28/2023Bank of AmericaBoost TargetUnderperform ➝ Underperform$1.78 ➝ $2.00
11/9/2023CIBCBoost TargetOutperform$2.75 ➝ $3.00
5/18/2023Roth CapitalReiterated RatingBuy
5/15/2023BarclaysLower Target$3.50 ➝ $3.00
3/1/2023Raymond JamesLower TargetOutperform$7.00 ➝ $3.00
11/8/2022Canaccord Genuity GroupLower TargetC$5.00 ➝ C$4.75
11/1/2022Sanford C. BernsteinInitiated CoverageMarket Perform$3.00
9/30/2022BarclaysLower TargetEqual Weight$5.00 ➝ $3.50
7/29/2022Raymond JamesReiterated RatingBuy$7.00
7/28/2022Canaccord Genuity GroupUpgradeHold ➝ Buy
5/11/2022Canaccord Genuity GroupUpgradeSell ➝ HoldC$4.50
5/11/2022CIBCUpgradeNeutral ➝ Sector Outperform
5/9/2022Raymond JamesBoost TargetOutperform$5.00 ➝ $6.00
3/22/2022BarclaysUpgradeUnderweight ➝ Equal Weight$5.00
3/7/2022Piper SandlerLower TargetNeutral$4.00 ➝ $3.00
3/2/2022Raymond JamesSet TargetOutperform$5.00
2/22/2022Raymond JamesLower TargetOutperform$11.00 ➝ $5.00
2/22/2022Canaccord Genuity GroupLower TargetSell$7.00 ➝ $4.25
2/22/2022Stifel NicolausLower Target$6.50 ➝ $4.00
2/22/2022Piper SandlerLower TargetNeutral$7.00 ➝ $4.00
1/27/2022Jefferies Financial GroupUpgradeUnderperform ➝ Hold$5.54 ➝ $3.24
12/17/2021Raymond JamesReiterated RatingOutperform$14.00
11/18/2021Bank of AmericaInitiated CoverageUnderperform$5.00
11/18/2021BarclaysInitiated CoverageUnderweight$5.50
10/21/2021Raymond JamesSet TargetOutperform$11.00
8/24/2021Raymond JamesSet TargetOutperform$11.00
8/9/2021Raymond JamesSet TargetOutperform$11.00
6/15/2021Raymond JamesSet TargetOutperform$11.00
6/7/2021Raymond JamesReiterated RatingOutperform$11.00
5/10/2021Raymond JamesSet TargetOutperform$11.00
4/28/2021Bank of AmericaInitiated CoverageUnderperform
4/26/2021Raymond JamesSet TargetOutperform$11.00
3/1/2021Raymond JamesSet TargetOutperform$11.00
2/22/2021CIBCDowngradeOutperform ➝ Neutral$8.00 ➝ $12.50
2/4/2021Stifel NicolausReiterated RatingHold$8.00
11/17/2020Raymond JamesBoost TargetOutperform$10.00 ➝ $11.00
11/16/2020Jefferies Financial GroupLower TargetUnderperform$5.60 ➝ $5.00
11/6/2020Raymond JamesSet TargetOutperform$10.00
9/14/2020Raymond JamesSet TargetOutperform$10.00
9/8/2020Raymond JamesSet TargetOutperform$10.00
9/2/2020Raymond JamesSet TargetOutperform$10.00
8/18/2020Raymond JamesSet TargetOutperform$10.00
8/7/2020Raymond JamesSet TargetOutperform$10.00
6/23/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$6.50 ➝ $13.52
5/22/2020Raymond JamesSet TargetMarket Perform$6.50
5/11/2020Pi FinancialReiterated RatingHold$8.50
5/11/2020Raymond JamesSet TargetMarket Perform$6.50
5/11/2020Stifel NicolausLower TargetHold$8.00 ➝ $7.50
4/27/2020Raymond JamesDowngradeOutperform ➝ Market Perform$10.50 ➝ $6.50
4/19/2020Piper SandlerDowngradeOverweight ➝ Neutral
4/13/2020Piper SandlerDowngradeOverweight ➝ Neutral$12.00 ➝ $7.00
4/2/2020Bank of AmericaDowngradeBuy ➝ Neutral$9.00
3/4/2020MKM PartnersUpgradeNeutral ➝ Buy$12.00 ➝ $11.00
3/3/2020Stifel NicolausDowngradeBuy ➝ Hold$12.00 ➝ $8.00
12/21/2019Raymond JamesSet TargetOutperform$12.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 13 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 8 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 1 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Cronos Group logo
Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Read More

Today's Range

Now: $1.95
Low: $1.86
High: $1.97

50 Day Range

MA: $2.08
Low: $1.87
High: $2.29

52 Week Range

Now: $1.95
Low: $1.86
High: $3.14

Volume

1,906,763 shs

Average Volume

1,848,104 shs

Market Capitalization

$745.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Cronos Group?

The following equities research analysts have issued stock ratings on Cronos Group in the last twelve months: Bank of America Co., and CIBC.
View the latest analyst ratings for CRON.

What is the current price target for Cronos Group?

0 Wall Street analysts have set twelve-month price targets for Cronos Group in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 53.8%. CIBC has the highest price target set, predicting CRON will reach $3.50 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $2.50 for Cronos Group in the next year.
View the latest price targets for CRON.

What is the current consensus analyst rating for Cronos Group?

Cronos Group currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe CRON will underperform the market and that investors should sell shares of Cronos Group.
View the latest ratings for CRON.

What other companies compete with Cronos Group?

Other companies that are similar to Cronos Group include Merus, Twist Bioscience, ACADIA Pharmaceuticals, Vericel and MorphoSys. Learn More about companies similar to Cronos Group.

How do I contact Cronos Group's investor relations team?

Cronos Group's physical mailing address is 111 PETER STREET SUITE 300, TORONTO A6, M5V 2G9. The company's listed phone number is (416) 504-0004 and its investor relations email address is [email protected]. The official website for Cronos Group is www.thecronosgroup.com. Learn More about contacing Cronos Group investor relations.